Earlier this year, I wrote about one of psychiatry’s most unusual drug-development stories: a psychedelic compound first identified in the defensive secretions of the Sonoran Desert toad that has now entered the realm of randomized clinical trials for severe depression. The field has advanced dramatically beyond the early period when the compound was known primarily through recreational use and colorful names such as Bufo, Sapito, “the toad,” and even “the Joe Rogan psychedelic.” Today’s scientific story, however, has surprisingly little to do with the toad itself.
Many medicines began with unexpected observations in nature. Aspirin originated from willow bark. Penicillin emerged from mold. Psilocybin was isolated from naturally occurring mushrooms; GLP-1 receptor agonists owe part of their development to studies of Gila monster saliva. In each case, scientists did not simply use the natural source—they identified the active molecule, developed standardized pharmaceutical formulations, and rigorously tested them. The story of 5-MeO-DMT appears to be following that same path.
The first randomized, placebo-controlled Phase 2b trial of inhaled synthetic 5-MeO-DMT has now reported robust antidepressant effects in patients with treatment-resistant depression, moving the field well beyond the small open-label studies that initially generated excitement. Cubala and colleagues’ study is now the landmark clinical study in the field. Participants experienced large reductions in depression severity, remission rates approaching 60 percent after a single treatment day, and no serious adverse events during the blinded phase. Psychiatric researchers have searched for faster and more effective antidepressants for decades. These findings represent an important milestone.
If ongoing studies continue to confirm clinical benefit, psychiatry may be looking at a carefully supervised intervention measured in minutes rather than months.
The momentum became even more apparent when Eli Lilly disclosed plans to acquire AtaiBeckley for up to $3.8 billion, largely to obtain BPL-003, an intranasal formulation of synthetic 5-MeO-DMT. Of course, a multibillion-dollar acquisition does not guarantee FDA approval. But when one of the world’s largest neuroscience companies believes the science has matured enough to justify a major investment, attention is paid. The attraction is not simply to acquire another psychedelic. The possibility is far more ambitious: a medicine that can be administered in less than 30 minutes yet produce antidepressant benefits lasting weeks—or perhaps months—after a single supervised treatment.
More broadly, the acquisition indicates a changing landscape in psychiatry. Psychedelic medicines have moved outside academic laboratories and small biotechnology companies into mainstream pharmaceutical development. Just as Janssen’s development of esketamine helped establish rapid-acting antidepressants, Lilly’s investment may accelerate the next generation of neuroplasticity-based therapies.
A Different Therapeutic Model
Perhaps the most intriguing aspect of 5-MeO-DMT is not that it appears to act rapidly—it’s how brief the treatment itself may be.
Traditional antidepressants typically require daily administration for weeks before patients experience meaningful improvement. Ketamine can produce relief within hours but generally requires repeated infusions or intranasal treatments, with each visit involving prolonged monitoring. By contrast, inhaled synthetic 5-MeO-DMT produces an intense but remarkably brief psychedelic experience, usually lasting only 15 to 30 minutes. If larger studies verify that combination of rapid-onset, short treatment duration, and durable benefit, 5-MeO-DMT could become one of the most practical psychedelic-assisted therapies currently under development.
Despite encouraging findings, many important questions remain. One challenge is that psychedelic trials are inherently difficult to blind. Most participants can recognize whether they received an active psychedelic, making expectancy effects difficult to separate from true pharmacologic benefit. Investigators are refining study designs to minimize this limitation.
Durability is also still uncertain. How long will improvement last after a single treatment? Which patients will require repeat dosing? Can additional treatments safely maintain remission?
These questions will become increasingly important as larger Phase 3 trials move forward.
Safety also deserves continued attention. The experience with synthetic 5-MeO-DMT has been reassuring when treatment occurs under carefully controlled medical conditions. In these studies, patients are carefully screened before treatment. People with a personal or family history of bipolar disorder or schizophrenia are generally not enrolled. Participants receive a standardized pharmaceutical formulation and are monitored by experienced clinical teams before, during, and after treatment.
That is very different from recreational use or the use of natural toad secretions.
Outside of research or specialized treatment settings, there is no careful screening, no standardized dose, and no medical supervision. People may use unknown or impure preparations, combine them with other drugs or alcohol, or have underlying psychiatric or medical conditions that increase the risk of serious adverse effects, including prolonged psychological distress or psychosis in susceptible individuals.
As with electroconvulsive therapy, ketamine, transcranial magnetic stimulation, and every major advance in psychiatry before them, the full safety profile of synthetic 5-MeO-DMT will become clear only through larger clinical trials, longer follow-up, and, if approved, careful post-marketing surveillance.
A New Way of Thinking About Depression
Psychiatry has customarily relied on medications taken every day to gradually modify brain chemistry. But psychedelic-assisted therapies suggest a different possibility: brief interventions capable of producing rapid and potentially lasting changes in brain circuits involved in mood, cognition, and affective processing. Exactly how these benefits occur remains an active area of investigation. They may reflect enhanced neuroplasticity, profound psychological experiences, or—as is often true in medicine—a blend of biological and psychological systems working together.
From my perspective, one of the most interesting possibilities is that psychedelics may help shift the brain from a maladaptive depressive state toward a healthier adaptive state. Whether this represents true circuit remodeling, psychological transformation, or both remains an important question for future research.
One useful way to appreciate the potential of 5-MeO-DMT is to compare it with other rapidly acting investigational antidepressants. Ketamine can relieve depressive symptoms within hours but generally requires repeated treatment sessions lasting one to two hours, including monitoring. Psilocybin-assisted therapy, the most studied psychedelic treatment for treatment-resistant depression, has demonstrated encouraging and durable antidepressant effects after one or two sessions. But psilocybin treatment usually requires six or more hours of clinical supervision. LSD is also under investigation for depression and anxiety, but its effects often extend 8 to 12 hours, making treatment considerably more demanding for both patients and treatment centers.
By comparison, inhaled synthetic 5-MeO-DMT typically produces an intense psychedelic experience lasting only 15 to 30 minutes, yet early clinical trials suggest antidepressant benefits that may persist well beyond the acute drug experience. Whether its ultimate efficacy matches or exceeds these other psychedelics or treatments with fewer side effects remains unknown.
Medicine advances by replacing intriguing observations with rigorous evidence. Synthetic 5-MeO-DMT has now crossed that threshold. Whether it ultimately becomes an approved antidepressant is still uncertain, but randomized clinical trials—not anecdotes—are now driving the conversation.
Whether BPL-003 ultimately succeeds will depend on Phase 3 trials, long-term safety, and regulatory review. But one thing has already changed. The conversation has shifted from folklore to pharmacology, from anecdote to randomized clinical trials, and from curiosity to one of the most closely watched programs in modern neuropsychopharmacology. The story may have begun with a desert toad. Its future will be decided by science.